| 2.92 -0.01 (-0.34%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.19 | 1-year : | 4.89 |
| Resists | First : | 3.58 | Second : | 4.19 |
| Pivot price | 2.46  |
|||
| Supports | First : | 2.51 | Second : | 1.85 |
| MAs | MA(5) : | 2.93 |
MA(20) : | 2.44 |
| MA(100) : | 1.63 |
MA(250) : | 1.87 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 68.9  |
D(3) : | 79.7 |
| RSI | RSI(14): 64.4 |
|||
| 52-week | High : | 3.58 | Low : | 0.81 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MAIA ] has closed below upper band by 21.0%. Bollinger Bands are 155.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.21 - 3.23 | 3.23 - 3.25 |
| Low: | 2.82 - 2.84 | 2.84 - 2.86 |
| Close: | 2.89 - 2.92 | 2.92 - 2.95 |
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
Wed, 01 May 2024
MAIA Biotech director acquires additional shares By Investing.com - Investing.com
Tue, 30 Apr 2024
MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement - Business Wire
Mon, 29 Apr 2024
MAIA Biotechnology Shares Hit 52-Week High After Director Stock Purchase - MarketWatch
Fri, 26 Apr 2024
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Acquires $39,919.95 in Stock - MarketBeat
Fri, 26 Apr 2024
Maia Biotechnology director Smith acquires shares worth $299,408 By Investing.com - Investing.com
Sun, 21 Apr 2024
MAIA Biotechnology, Inc. announced that it expects to receive $0.664994 million in funding - Marketscreener.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 24.3 (%) |
| Held by Institutions | 1.8 (%) |
| Shares Short | 179 (K) |
| Shares Short P.Month | 302 (K) |
| EPS | -1.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -103.3 % |
| Return on Equity (ttm) | -243.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -2.03 |
| PEG Ratio | 0 |
| Price to Book value | 14.6 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|